Search

439 results for "lecanemab".

Research summaries 393

Showing the best 200 of 393, 81–90, page 9 of 20. Filter these by subject, year and score in the research library →

1. Bildgebungsanomalien bei Alzheimer-Therapie mit LecanemabResearch summary

   Research summaries · alzhub.org/study/bildgebungsanomalien-bei-alzheimer-therapie-mit-lecanemab-b85e6325

   … monoklonale Antikörper Lecanemab beugt diesen Plaques vor, indem er lösliche Beta-Amyloid-Fibrillen bindet und deren Clearance fördert. Allerdings begünstigen solche Antiamyloidtherapien ARIA (amyloid-related imaging …

2. Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/fatal-iatrogenic-cerebral-amyloid-related-arteritis-in-a-woman-38086820

   … the experimental drug lecanemab. She was randomized to the placebo group and subsequently enrolled in an open-label extension which guaranteed she received the active drug. After the third biweekly infusion, she suffered a …

3. Lecanemab Binds to Transgenic Mouse Model‐Derived Amyloid‐β Fibril Structures Resembling Alzheimer's Disease Type I, Type II and Arctic FoldsResearch summary

   Research summaries · alzhub.org/study/lecanemab-binds-to-transgenic-mouse-modelderived-amyloid-fibril-40495448

   Our results show that lecanemab exhibits high binding affinity to amyloid-β fibril structures that have a flexible N-terminus in common, as is the case for type I, type II and murine type III amyloid-β fibril polymorphs, which …

4. Lecanemab Therapy Use Patterns for Alzheimer's Disease Among Early Initiators in a Large National Health PlanResearch summary

   Research summaries · alzhub.org/study/lecanemab-therapy-use-patterns-for-alzheimer-s-disease-among-early-41139687

   Lecanemab, an anti-amyloid monoclonal antibody, has been approved for treatment of early Alzheimer's disease. However, real-world data remain limited regarding use. Using data from a large national health plan with primarily …

5. Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brainsResearch summary

   Research summaries · alzhub.org/study/lecanemab-demonstrates-highly-selective-binding-to-a-protofibrils-38906341

   … imaging abnormalities. Lecanemab is a humanized IgG1 antibody that was developed to target the soluble Aβ protofibril conformation. The present study prepared extracts of post mortem brain samples from AD patients and …

6. Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in CanadaResearch summary

   Research summaries · alzhub.org/study/lecanemab-donanemab-and-emerging-disease-modifying-therapies-for-1b2f6657

   Monoclonal antibodies such as lecanemab and donanemab show reduction in amyloid plaque and slowing of cognitive and functional decline (modest) in early AD (mild cognitive impairment or mild dementia). In contrast, Aducanumab …

7. Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilanceResearch summary

   Research summaries · alzhub.org/study/long-term-surveillance-of-the-anti-amyloid-monoclonal-antibody-40217276

   The anti-amyloid monoclonal antibody lecanemab received the US accelerated approval for mild cognitive impairment or mild dementia stage of Alzheimer disease in January 2023, which was converted into traditional approval in June …

8. Symptomatic lobar intracerebral hemorrhage during extended lecanemab treatment: A case reportResearch summary

   Research summaries · alzhub.org/study/symptomatic-lobar-intracerebral-hemorrhage-during-extended-lecanemab-42877463

   Lecanemab is an anti-amyloid-β protofibril antibody that slows cognitive decline in early Alzheimer's disease. Although amyloid-related imaging abnormalities (ARIA) occur predominantly early in treatment, reports of hemorrhagic …

9. The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary NotesResearch summary

   Research summaries · alzhub.org/study/the-anti-amyloid-monoclonal-antibody-lecanemab-16-cautionary-notes-37334596

   After the CLARITY-AD clinical trial results of lecanemab were interpreted as positive, and supporting the amyloid hypothesis, the drug received accelerated Food and Drug Administration approval. However, we argue that benefits of …

10. Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemabResearch summary

    Research summaries · alzhub.org/study/balancing-benefit-and-risk-in-early-alzheimer-s-disease-the-european-41852829

    … regulatory approvals of lecanemab and donanemab in the EU mark a significant milestone. Both antibodies, developed within the amyloid hypothesis, demonstrated statistically significant effects on cognitive and functional outcomes …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-13. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.